Mutations in Patients With Nonsevere Hemophilia and Inhibitors
Location . | Mutation . | Factor VIII Level (%) . | Reference . | |||
---|---|---|---|---|---|---|
Domain . | Exon . | Codon . | Codon/Amino Acid . | VIII:C . | VIII:Ag . | . |
A1 | 5 | 198 | CTT to CAT | 2 | 5 | |
Leu to His | ||||||
Pieneman et al19 | ||||||
A2 | 12 | 593 | CGC to TGC | 9 | 13 | |
Arg to Cys | ||||||
A2 | 14 | 701 | GGC to AGC | 2 | — | Bidichandani et al20 |
Gly to Asp | ||||||
A3 | 14 | 1689 | CGC to CAC | 11 | 100 | Schwaab et al21 |
Arg to His | ||||||
C1 | 2 | 2150 | CGT to CAT | 12 | — | Santagostino et al22* |
Arg to His | ||||||
C2 | 24 | 2209 | CGA to CAA | 7 | 130 | Schwaab et al23* |
Arg to Gln | ||||||
C2 | 25 | 2229 | TGG to TGT | 3 | — | Naylor et al24 |
Trp to Cys |
Location . | Mutation . | Factor VIII Level (%) . | Reference . | |||
---|---|---|---|---|---|---|
Domain . | Exon . | Codon . | Codon/Amino Acid . | VIII:C . | VIII:Ag . | . |
A1 | 5 | 198 | CTT to CAT | 2 | 5 | |
Leu to His | ||||||
Pieneman et al19 | ||||||
A2 | 12 | 593 | CGC to TGC | 9 | 13 | |
Arg to Cys | ||||||
A2 | 14 | 701 | GGC to AGC | 2 | — | Bidichandani et al20 |
Gly to Asp | ||||||
A3 | 14 | 1689 | CGC to CAC | 11 | 100 | Schwaab et al21 |
Arg to His | ||||||
C1 | 2 | 2150 | CGT to CAT | 12 | — | Santagostino et al22* |
Arg to His | ||||||
C2 | 24 | 2209 | CGA to CAA | 7 | 130 | Schwaab et al23* |
Arg to Gln | ||||||
C2 | 25 | 2229 | TGG to TGT | 3 | — | Naylor et al24 |
Trp to Cys |
Factor VIII abbreviations are as in Table 1.
Maximal inhibitor titer reported and >100 BU/mL.